AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $158,194,657 | -6.3% | 13,009,429 | -3.2% | 0.02% | -5.6% |
Q2 2023 | $168,836,431 | +10.9% | 13,442,391 | -2.1% | 0.02% | -5.3% |
Q1 2023 | $152,305,000 | +91975.0% | 13,733,485 | +1.4% | 0.02% | -13.6% |
Q4 2022 | $165,414 | -99.9% | 13,547,368 | -5.5% | 0.02% | +4.8% |
Q3 2022 | $149,685,000 | -12.1% | 14,337,705 | -9.6% | 0.02% | -12.5% |
Q2 2022 | $170,381,000 | +15.7% | 15,864,107 | +2.0% | 0.02% | +33.3% |
Q1 2022 | $147,275,000 | -16.9% | 15,551,816 | +1.4% | 0.02% | -10.0% |
Q4 2021 | $177,222,000 | +21.4% | 15,343,828 | +0.4% | 0.02% | +11.1% |
Q3 2021 | $145,954,000 | +14.0% | 15,283,058 | +15.0% | 0.02% | +20.0% |
Q2 2021 | $128,081,000 | +9.1% | 13,286,436 | +11.8% | 0.02% | -6.2% |
Q1 2021 | $117,373,000 | -39.9% | 11,879,824 | +40.4% | 0.02% | -44.8% |
Q4 2020 | $195,317,000 | +67.1% | 8,458,917 | +1.9% | 0.03% | +45.0% |
Q3 2020 | $116,874,000 | -3.6% | 8,300,766 | +3.2% | 0.02% | -13.0% |
Q2 2020 | $121,298,000 | +97.0% | 8,043,691 | +20.7% | 0.02% | +64.3% |
Q1 2020 | $61,575,000 | +62.2% | 6,664,006 | +71.0% | 0.01% | +100.0% |
Q4 2019 | $37,951,000 | +421.8% | 3,896,430 | +329.7% | 0.01% | +600.0% |
Q3 2019 | $7,273,000 | -29.6% | 906,685 | +5.4% | 0.00% | -50.0% |
Q2 2019 | $10,327,000 | -14.1% | 860,619 | -2.7% | 0.00% | 0.0% |
Q1 2019 | $12,023,000 | +40.1% | 884,107 | -1.3% | 0.00% | 0.0% |
Q4 2018 | $8,584,000 | -27.3% | 896,080 | -8.2% | 0.00% | 0.0% |
Q3 2018 | $11,806,000 | -18.6% | 976,456 | +5.1% | 0.00% | -33.3% |
Q2 2018 | $14,511,000 | -2.0% | 929,045 | -5.6% | 0.00% | 0.0% |
Q1 2018 | $14,800,000 | +3.9% | 984,023 | -0.6% | 0.00% | 0.0% |
Q4 2017 | $14,251,000 | -23.2% | 990,360 | -21.5% | 0.00% | -25.0% |
Q3 2017 | $18,551,000 | +43.7% | 1,262,000 | -1.5% | 0.00% | +33.3% |
Q2 2017 | $12,906,000 | +23.5% | 1,281,633 | -12.6% | 0.00% | +50.0% |
Q1 2017 | $10,452,000 | +48.0% | 1,465,914 | +3.2% | 0.00% | 0.0% |
Q4 2016 | $7,063,000 | +110.3% | 1,421,086 | +213.1% | 0.00% | +100.0% |
Q3 2016 | $3,358,000 | -38.0% | 453,851 | -54.3% | 0.00% | 0.0% |
Q2 2016 | $5,420,000 | -43.7% | 992,689 | -12.8% | 0.00% | -50.0% |
Q1 2016 | $9,619,000 | +8.4% | 1,138,342 | +24.4% | 0.00% | 0.0% |
Q4 2015 | $8,874,000 | +46.5% | 914,799 | +111.3% | 0.00% | 0.0% |
Q3 2015 | $6,058,000 | +119.7% | 433,039 | +70.9% | 0.00% | +100.0% |
Q1 2015 | $2,758,000 | +335.0% | 253,449 | -6.8% | 0.00% | – |
Q2 2013 | $634,000 | – | 271,811 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |